Alpha 2.0
Login Register
» Articles » PMID: 9593166

In Vitro Activities of Clinafloxacin Against Contemporary Clinical Bacterial Isolates from 10 North American Centers

Overview
Journal Antimicrob Agents Chemother
Publisher American Society for Microbiology
Specialty Pharmacology
Date 1998 May 21
PMID 9593166
Citations 11
Authors
P C Fuchs
A L Barry
S D Brown
Affiliations
Soon will be listed here.
Abstract

Clinafloxacin was more active than ciprofloxacin against 4,213 aerobic and facultative anaerobic bacterial isolates from 10 medical centers, as tested by broth microdilution and disk diffusion methods. The percentage of 201 anaerobes susceptible to clinafloxacin by broth microdilution was comparable to cefoxitin. Our data support the proposed disk diffusion interpretive criteria for aerobic bacteria with 5-microg clinafloxacin disks.

Citing Articles

A critical review of the fluoroquinolones: focus on respiratory infections.

Zhanel G, Ennis K, Vercaigne L, Walkty A, Gin A, Embil J Drugs. 2002; 62(1):13-59.

PMID: 11790155 DOI: 10.2165/00003495-200262010-00002.

Drug interactions with clinafloxacin.

Randinitis E, Alvey C, Koup J, Rausch G, Abel R, Bron N Antimicrob Agents Chemother. 2001; 45(9):2543-52.

PMID: 11502527 PMC: 90690. DOI: 10.1128/AAC.45.9.2543-2552.2001.

Clinafloxacin pharmacokinetics in subjects with various degrees of renal function.

Randinitis E, Koup J, Rausch G, Abel R, Bron N, Hounslow N Antimicrob Agents Chemother. 2001; 45(9):2536-42.

PMID: 11502526 PMC: 90689. DOI: 10.1128/AAC.45.9.2536-2542.2001.

Pharmacokinetics of clinafloxacin after single and multiple doses.

Randinitis E, Brodfuehrer J, Eiseman I, Vassos A Antimicrob Agents Chemother. 2001; 45(9):2529-35.

PMID: 11502525 PMC: 90688. DOI: 10.1128/AAC.45.9.2529-2535.2001.

In vitro activities of six quinolones and mechanisms of resistance in Staphylococcus aureus and coagulase-negative staphylococci.

Linde H, Schmidt M, Fuchs E, Reischl U, Niller H, Lehn N Antimicrob Agents Chemother. 2001; 45(5):1553-7.

PMID: 11302827 PMC: 90505. DOI: 10.1128/AAC.45.5.1553-1557.2001.

References
1.
Wise R, Jones S, Das I, Andrews J . Pharmacokinetics and inflammatory fluid penetration of clinafloxacin. Antimicrob Agents Chemother. 1998; 42(2):428-30. PMC: 105427. DOI: 10.1128/AAC.42.2.428. View
2.
Fuchs P, Barry A, Pfaller M, Allen S, Gerlach E . Multicenter evaluation of the in vitro activities of three new quinolones, sparfloxacin, CI-960, and PD 131,628, compared with the activity of ciprofloxacin against 5,252 clinical bacterial isolates. Antimicrob Agents Chemother. 1991; 35(4):764-6. PMC: 245095. DOI: 10.1128/AAC.35.4.764. View
3.
Pankuch G, Jacobs M, Appelbaum P . Susceptibilities of 123 Xanthomonas maltophilia strains to clinafloxacin, PD 131628, PD 138312, PD 140248, ciprofloxacin, and ofloxacin. Antimicrob Agents Chemother. 1994; 38(2):369-70. PMC: 284459. DOI: 10.1128/AAC.38.2.369. View
4.
Wexler H, Molitoris E, Reeves D, Finegold S . In-vitro activity of clinafloxacin (CI-960) and PD 131628-2 against anaerobic bacteria. J Antimicrob Chemother. 1994; 34(4):579-84. DOI: 10.1093/jac/34.4.579. View
5.
Harrington G, Zarins L, Ramsey M, Bradley S, Kauffman C . Susceptibility of ciprofloxacin-resistant staphylococci and enterococci to clinafloxacin. Diagn Microbiol Infect Dis. 1995; 21(1):27-31. DOI: 10.1016/0732-8893(94)00143-k. View